If plastic surgeons move fat from point A (tummy) to point B (buttocks), then to deny this product would be to disrupt an entire industry.
Not. going. to. happen.
Approval is just a matter of time.
Conclusion
While significant advances have been made in the use of
growth factors for stimulation of hematopoietic reconsti-
tution, overall efficacy of this approach is limited. Cell
therapy offers the possibility of administering an
“
intelli-
gent
”
therapeutic which addresses the hematopoietic
needs of the host in real-time. Autologous SVF therapy,
such as the HemXellerate product, offers the possibility
of delivering a heterogenous population of endothelial
cells, mesenchymal stem cells, and other potential cells
of interest. Given the established safety and ease of
autologous SVF administration, it is anticipated that
the proposed procedure will be rapidly adopted by
the market.
